Ravens, Ursula

The Registry of the German Competence NETwork on Atrial Fibrillation: Patient characteristics and initial management

Nabauer, M., Gerth, A., Limbourg, T., Schneider, S., Oeff, M., Kirchhof, P., Goette, A., Lewalter, T., Ravens, U., Meinertz, T., et al. (2008) · Europace

Atrial Fibrillation Management and OutcomesAcute Ischemic Stroke Management

Cited by 427

Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association

Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., et al. (2007) · Europace

Atrial Fibrillation Management and OutcomesStatistical Methods in Clinical Trials

Cited by 293

Adipocyte Fatty Acid–Binding Protein Suppresses Cardiomyocyte Contraction: A New Link Between Obesity and Heart Disease

Lamounier-Zepter, V., Look, C., Alvarez, J., Christ, T., Ravens, U., Schunck, W.-H., Ehrhart-Bornstein, M., Bornstein, S. R., & Morano, I. (2009) · Circulation Research

Cardiovascular Disease and AdiposityCardiovascular Function and Risk Factors

Cited by 203

Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’

Kirchhof, P., Bax, J., Blomstrom-Lundquist, C., Calkins, H., Camm, A. J., Cappato, R., Cosio, F., Crijns, H., Diener, H.-C., Goette, A., et al. (2009) · European Heart Journal

Atrial Fibrillation Management and OutcomesCardiac Arrhythmias and Treatments

Cited by 202

Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial

Kirchhof, P., Andresen, D., Bosch, R., Borggrefe, M., Meinertz, T., Parade, U., Ravens, U., Samol, A., Steinbeck, G., Treszl, A., et al. (2012) · The Lancet

Atrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmias

Cited by 176

Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference

Kirchhof, P., Breithardt, G., Aliot, E., Al Khatib, S., Apostolakis, S., Auricchio, A., Bailleul, C., Bax, J., Benninger, G., Blomstrom-Lundqvist, C., et al. (2013) · Europace

Atrial Fibrillation Management and OutcomesCardiac Arrhythmias and Treatments

Cited by 141

Human Electrophysiological and Pharmacological Properties of XEN-D0101: A Novel Atrial-Selective Kv1.5/IKur Inhibitor

Ford, J., Milnes, J., Wettwer, E., Christ, T., Rogers, M., Sutton, K., Madge, D., Virag, L., Jost, N., Horvath, Z., et al. (2013) · Journal of Cardiovascular Pharmacology

Cardiac electrophysiology and arrhythmiasAtrial Fibrillation Management and Outcomes

Cited by 62

Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation

Loose, S., Mueller, J., Wettwer, E., Knaut, M., Ford, J., Milnes, J., & Ravens, U. (2014) · Frontiers in Pharmacology

Cardiac electrophysiology and arrhythmiasAtrial Fibrillation Management and Outcomes

Cited by 49

Antiarrhythmic therapy in atrial fibrillation

Ravens, U. (2010) · Pharmacology & Therapeutics

Atrial Fibrillation Management and OutcomesCardiac electrophysiology and arrhythmias

Cited by 48

Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations

Szél, T., Koncz, I., Jost, N., Baczkó, I., Husti, Z., Virág, L., Bussek, A., Wettwer, E., Ravens, U., Papp, J. G., et al. (2011) · European Journal of Pharmacology

Cardiac electrophysiology and arrhythmiasCardiac Arrhythmias and Treatments

Cited by 34